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Background
Pulmonary hypertension (PH) is a progressive and debil-
itating condition with a high rate of mortality. Riociguat
(BAY 63-2521) is a new drug in development for PH that
is well tolerated [1,2] and has superior efficacy to nitric
oxide in patients with PH [2]. Treatment recommenda-
tions for PH are based on combination therapies that
include warfarin. The aim of this study was to investigate
potential pharmacodynamic or pharmacokinetic interac-
tions of riociguat and warfarin.
Materials and methods
This single-centre, randomized, double-blind, placebo-
controlled, crossover, interaction study included healthy
male volunteers aged 18–45 years. Riociguat (2.5 mg) or
placebo was administered orally three times daily (t.i.d.)
for 10 days. Warfarin sodium (25 mg) was administered
as a single oral dose 21 days before the study and on the
7th day of treatment with riociguat or placebo.
Results
Twenty-one of the 30 subjects valid for safety analysis
reported a total of 89 treatment-emergent adverse events,
all of which were of mild (n = 64) or moderate (n = 25)
severity. No serious adverse events occurred. The most fre-
quently reported treatment-emergent adverse events con-
sidered to be related to riociguat and/or warfarin were
dyspepsia, headache, flatulence, nausea and vomiting.
Data from 22 volunteers were valid for pharmacodynamic
and pharmacokinetic analyses. A single dose of warfarin
did not affect the pharmacokinetics of riociguat to a clini-
cally relevant extent (Table 1). Riociguat at steady state did
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Prothrombin time following a single oral dose of warfarin  sodium and multiple oral doses of riociguat or placebo Figure 1
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not affect Factor VII clotting activity or prothrombin time
(Table 1, Figure 1), and did not affect the pharmacokinet-
ics of warfarin (Table 1). Thus, riociguat and warfarin can
be combined in patients with PH, with no requirement
for dose adaptation.
A single dose of warfarin was administered on day 7.
Doses of riociguat or placebo were administered three
times daily on days 1–10. Geometric means are shown,
with upward bars denoting geometric means*geometric
standard deviations and downward bars denoting geo-
metric means/geometric standard deviations.
Conclusion
The combined use of riociguat with warfarin had a favour-
able safety profile. Riociguat at a dose of 2.5 mg t.i.d. dem-
onstrated no pharmacodynamic interactions and no
clinically relevant pharmacokinetic interactions with war-
farin. Thus, the combined use of riociguat with warfarin is
not expected to represent a risk and no dose adaptation is
required.
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Table 1: Pharmacokinetic and clotting profile parameter ratios of least squares means for warfarin and riociguat
Ratios Analyte Parameter Ratio (90% CI)
(Warfarin + riociguat)/(warfarin + placebo) R-warfarin AUC (g.h/L) 1.01 (0.96–1.05)
Cmax (g/L) 1.02 (0.96–1.08)
S-warfarin AUC (g.h/L) 1.01 (0.97–1.04)
Cmax (g/L) 1.01 (0.95–1.09)
Prothrombin time AUC(0–96) (s.h) 0.99 (0.97–1.01)
Factor VII % clotting activity AUC(0–96) (%.h) 1.03 (1.00–1.06)
(Warfarin + riociguat)/riociguat Riociguat AUC,ss (g.h/L) 0.96 (0.87–1.06)
Cmax,SS (g/L) 0.84 (0.70–1.01)
AUC, area under the plasma concentration-time curve from zero to infinity after single dose administration; AUC,ss, AUC at steady state; AUC(0–96), 
AUC from zero to 96 h after administration of warfarin; CI, confidence interval; Cmax, maximum drug concentration in plasma after single dose 
administration; Cmax,SS, Cmax at steady state.